These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1794617)

  • 1. Inactivation of retroviruses in biologicals manufactured for human use.
    Hilfenhaus J; Gregersen JP; Müller H; Nowak T; Pranter W
    Dev Biol Stand; 1991; 75():159-69. PubMed ID: 1794617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of removal of human retroviruses.
    Marcus-Sekura CJ
    Dev Biol Stand; 1991; 75():133-43. PubMed ID: 1794615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human retroviruses and herpesviruses: problems and solutions in safety testing of biologicals.
    Onions D; Lees G
    Dev Biol Stand; 1991; 75():145-58. PubMed ID: 1794616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of removal of human retroviruses.
    Marcus-Sekura CJ
    Dev Biol Stand; 1992; 76():215-23. PubMed ID: 1478339
    [No Abstract]   [Full Text] [Related]  

  • 5. Validation of purification procedures for removing and/or inactivating viruses in biologicals: points to consider.
    Vicari G
    Dev Biol Stand; 1991; 75():227-32. PubMed ID: 1794625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals.
    Farshid M; Taffs RE; Scott D; Asher DM; Brorson K
    Curr Opin Biotechnol; 2005 Oct; 16(5):561-7. PubMed ID: 16095899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of AIDS-causing retroviruses by the manufacturing procedures for human plasma proteins.
    Hilfenhaus J; Gregersen JP
    Behring Inst Mitt; 1988 Apr; (82):82-93. PubMed ID: 3044347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
    Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
    J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.
    Kozak RW; Golker CF; Stadler P
    Dev Biol Stand; 1996; 88():257-64. PubMed ID: 9119148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of HIV-1 and HIV-2 by various manufacturing procedures for human plasma proteins.
    Hilfenhaus JW; Gregersen JP; Mehdi S; Volk R
    Cancer Detect Prev; 1990; 14(3):369-75. PubMed ID: 2117485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
    Goldsmith JC
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction to the issues: detection of retroviruses and associated risks.
    Marcus-Sekura CJ
    Dev Biol Stand; 1992; 76():137-40. PubMed ID: 1478334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hazards of retroviruses associated with monoclonal antibody production.
    Thornton DH; Nicholas RA
    Dev Biol Stand; 1984; 57():9-12. PubMed ID: 6526154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HIV safety of commercially produced human plasma proteins].
    Hilfenhaus J
    Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():84-8. PubMed ID: 8000262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Theoretical and technical concerns in inactivation/elimination of viruses in plasma derivatives.
    Hilfenhaus J; Niedrig M; Nowak T
    Dev Biol Stand; 1993; 81():117-23. PubMed ID: 8174794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Affinity chromatography to remove viruses during preparation of plasma derivatives.
    Lawrence JE
    Dev Biol Stand; 1993; 81():191-7. PubMed ID: 8174803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of cell substrates for the production of biologicals: Revision of WHO recommendations. Report of the WHO Study Group on Cell Substrates for the Production of Biologicals, 22-23 April 2009, Bethesda, USA.
    Knezevic I; Stacey G; Petricciani J; Sheets R;
    Biologicals; 2010 Jan; 38(1):162-9. PubMed ID: 19818645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Process changes and their effect on process evaluation for viral clearance.
    Marcus-Sekura C
    Dev Biol Stand; 1996; 88():125-30. PubMed ID: 9119123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of quantitative PCR assays for biologicals: quality and safety evaluation.
    Xu Y; Brorson K
    Dev Biol (Basel); 2003; 113():89-98. PubMed ID: 14620857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral safety of solvent-detergent treated blood products.
    Horowitz B; Prince AM; Horowitz MS; Watklevicz C
    Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.